Carl Zeiss AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Carl Zeiss AG
In his recent report on Alcon, BTIG analyst Ryan Zimmerman estimated that its pharmaceutical portfolio could generate close to $900m in fiscal year 2022.
Swiss-based Vivior AG has developed a wearable Visual Behavior Monitor (VBM) designed to help surgical ophthalmologists determine the best treatment options for patients. The company's initial target is the $2.15bn global refractive and cataract surgery market.
Medtech M&A activity slowed in the last month of summer with just 16 mergers and acquisitions recorded on the Medtech Insight M&A Deal Tracker. However, the month included one billion-dollar deal and several deals in the ophthalmological sector.
OcuSciences Inc.'s OcuMet Beacon is a noninvasive and rapid diagnostic screening tool for retinal disease. The current ophthalmic standard of care, optical coherence tomography, evaluates structural change in retinal thickness or swelling after retinal damage has occurred, but OcuMet can provide a level of functional testing before damage occurs, which is especially important for latent diabetics or patients undiagnosed for retinal diseases.
- Medical Devices
- Other Names / Subsidiaries
- Carl Zeiss AG are: Carl Zeiss Meditec AG, Carl Zeiss Vision GmbH, Carl Zeiss SMT GmbH, Carl Zeiss IMT GmbH, Carl Zeiss Microscopy GmbH.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.